- Conditions
- Advanced Cancers
- Interventions
- Telephone Survey
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 5,895
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
- Device · Drug
- Lead sponsor
- NovoCure GmbH
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 20 more
- Conditions
- Advanced Solid Tumors
- Interventions
- AMG 355, Pembrolizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Azacitidine 30mg/m2, Entinostat, Azacitidine 40mg/m2
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • Baltimore, Maryland
- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Interventions
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more
- Conditions
- Lung Cancer, Bladder Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Breast Cancer
- Interventions
- Communication of Patients Lost to Follow-up to Providers
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Hines, Illinois • Minneapolis, Minnesota + 2 more
- Conditions
- Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma, Metastatic Melanoma, Locally Advanced Renal Cell Carcinoma, Metastatic Clear-Cell Renal Cell Carcinoma
- Interventions
- Retifanlimab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 18
- States / cities
- Fresno, California • San Marcos, California • Santa Rosa, California + 13 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
- Interventions
- Best Practice, Informational Intervention, Questionnaire Administration
- Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Female Reproductive System Neoplasm, Malignant Neoplasm
- Interventions
- Communication Intervention, Educational Intervention, Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Anxiety, No Evidence of Disease, Lung Carcinoma
- Interventions
- educational intervention, questionnaire administration, quality-of-life assessment, Best Practice
- Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Lung Diseases, Cancer
- Interventions
- Combination Treatment - Cohort 1, Combination Treatment - Cohort 2, Combination Treatment - Cohort 3, Combination Treatment - Cohort 4
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- M7824, Pembrolizumab
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Los Angeles, California • Orange, California + 21 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- erlotinib, hydroxychloroquine
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- oral cell DNA adducts
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- Oral repotrectinib (TPX-0005)
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 49
- States / cities
- Duarte, California • Glendale, California • La Jolla, California + 36 more
- Conditions
- NSCLC Stage II, NSCLC, Stage III
- Interventions
- Precision Exercise Regimen for Cancer Care (PERCC)
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Galveston, Texas • Salt Lake City, Utah
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 62
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Bioview, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Frederick, Maryland • Bethlehem, Pennsylvania
- Conditions
- Lung Cancer
- Interventions
- Shared Decision Making
- Behavioral
- Lead sponsor
- Christiana Care Health Services
- Other
- Eligibility
- 55 Years to 78 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Advanced Cancer
- Interventions
- MGCD516
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 33 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Alectinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
- Interventions
- 177Lu-J591
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Non-Small Cell Carcinoma, Thoracic Cancer
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California